Crossmark

Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial

Crossref DOI link: https://doi.org/10.1007/s40618-025-02665-7

Published Online: 2025-07-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Luo, Yi

Ding, Bo

Xia, Wen-qing

Liu, Bing-li

Ge, Sheng-hui

Yuan, Lu

Ma, Jian-hua https://orcid.org/0000-0001-9383-2559
Funding

Funding for this research was provided by:

Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau (ZKX22038)
License Information

Text and Data Mining valid from 2025-07-28

Version of Record valid from 2025-07-28
More Information

Article History

Received: 22 April 2025

Accepted: 19 July 2025

First Online: 28 July 2025

Declarations

:

: All authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below